Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton, Jr. Buys 10,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were purchased at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the purchase, the director owned 996,967 shares in the company, valued at $2,721,719.91. This trade represents a 1.01% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Anixa Biosciences Stock Performance

Shares of Anixa Biosciences stock opened at $2.80 on Tuesday. Anixa Biosciences Inc has a 52 week low of $2.32 and a 52 week high of $5.46. The stock has a 50 day moving average price of $3.33 and a two-hundred day moving average price of $2.98. The stock has a market capitalization of $97.34 million, a PE ratio of -8.75 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). Research analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds have recently bought and sold shares of ANIX. Integrated Wealth Concepts LLC bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth $30,000. Corient Private Wealth LP raised its holdings in shares of Anixa Biosciences by 87.0% in the second quarter. Corient Private Wealth LP now owns 37,400 shares of the company’s stock valued at $105,000 after purchasing an additional 17,400 shares during the last quarter. AXQ Capital LP bought a new position in shares of Anixa Biosciences during the second quarter valued at about $41,000. Canada Pension Plan Investment Board bought a new position in shares of Anixa Biosciences during the second quarter valued at about $38,000. Finally, Sanctuary Advisors LLC purchased a new position in Anixa Biosciences during the second quarter worth about $29,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on ANIX shares. Weiss Ratings lowered shares of Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. HC Wainwright reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.